^
    Back
    Association details:
    Biomarker:PIK3CA H1047R
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Mekinist (trametinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Oncotarget
    Title:

    A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers

    Excerpt:
    Combination of rapamycin with trametinib, a MEK1/2 inhibitor, demonstrated strong synergism in HNSCC-derived cells in vitro and in vivo, including HNSCC cells expressing the HRAS and PIK3CA oncogenes….We used UM-SCC-17B, which has a HRAS Q61L mutant and Detroit 562 cells exhibiting the PIK3CA H1047R mutation. The combination of rapamycin and trametinib demonstrated strong synergism in growth inhibition of these cells (Figure ​(Figure2A,2A, Supplementary Figure S1A).
    Secondary therapy:
    nanoparticle albumin-bound rapamycin
    DOI:
    10.18632/oncotarget.7372
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    JAMA Otolaryngol Head Neck Surg
    Title:

    Response of Head and Neck Squamous Cell Carcinoma Cells Carrying PIK3CA Mutations to Select Targeted Therapies

    Excerpt:
    CONTRADICTED EVIDENCE...we also tested the response of our engineered cell lines to trametinib, which is a selective inhibitor of MEK 1/MEK2 activation and kinase activity. Similar to the trends with 17-AAG and GDC-0941, E545K- and H1047R-SCC25 cells exhibited decreased sensitivity to trametinib
    DOI:
    10.1001/jamaoto.2015.0471